Gerald L. Andriole, MD, presented “Non-Metastatic CRPC: Finding Advanced Disease with Next Gen Imaging Matters” during the Perspectives in Urology: Point Counterpoint 2020 virtual conference in November 2020.
How to cite: Andriole, Gerald L. “Non-Metastatic CRPC: Finding Advanced Disease with Next Gen Imaging Matters.” November 2020. Accessed May 2021. https://dev.grandroundsinurology.com/non-metastatic-crpc-finding-advanced-disease-with-next-gen-imaging-matters/
Non-Metastatic CRPC: Finding Advanced Disease with Next Gen Imaging Matters – Summary
Gerald L. Andriole, Jr., MD, the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri, defines non-metastatic castration-resistant prostate cancer (nmCRPC) as having rising PSA measurements on three consecutive measurements with a PSA of greater than two. He also defines next-generation imaging as PET scans. He discusses FACBC scans and PSMA-based PET scans, as well as the history and treatment of nmCRPC. Dr. Andriole reviews the SABR-COMET study, the STOMP trial, and the ORIOLE study. He concludes that next-generation imaging is necessary for patients with nmCRPC, that metastasis-directed therapy shows benefits, and that larger and longer trials are warranted.
About the Perspectives in Urology: Point Counterpoint 2020 virtual conference:
Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, as well as Program Co-Chair Dan Theodorescu, MD, PhD, this virtual conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This two-day interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking. A focus on prostate cancer was given on Wednesday, November 11th, with a focus on bladder cancer given on Thursday, November 12th.